Abstract:Abstract Liver cancer is the 5th most common cancer type and the 3rd leading cause of cancer related death worldwide. In the US, the number of new cases continues to rise and reached 19,000 per year in 2004, more than doubling the number twenty years ago. The limited treatment options include surgery, radiation therapy and chemotherapy. Unfortunately, the prognosis for most liver cancer patients is extremely poor due to late diagnosis, and the 5 year overall survival rate is less than 10%. Recent approval of sorafenib suggests that VEGFR inhibition might be beneficial to the survival of HCC patients. Hepatocellular carcinoma (HCC) originates from hepatocytes and accounts for 80–90% of the cases of liver cancer. Genetic alterations found in human HCCs include loss of major tumor suppressor genes (p53, Ink4a/Arf, PTEN, and NF1) as well as activation of oncogenic pathways through mutation and/or amplification (RAS/MapK, PI3K, and Wnt/beta-catenin pathways). We generated primary HCCs in mouse using a recently-developed tissue reconstitution approach. Briefly, we isolated hepatoblasts from p53 deficient donor embryos, infected the cells with retroviruses carrying the clinically relevant human oncogenes Myc or mutant Kras, and transplanted them back to the liver of recipient mice through intra-splenic injection. These mice developed tumors in the liver with a latency of 2–5 months and penetrance of 30–50%. Histological examination demonstrated that these tumors resemble the features of human HCCs. Interestingly, a quantitative analysis of the vasculature in these tumors revealed a broad range of vessel size and vessel density, indicating that angiogenesis in these tumors are likely driven by different molecular mechanisms. We sought to explore the variation in angiogenic phenotypes by examining the response of various tumors with the ATP competitive small molecule VEGFR inhibitor tivozanib (AV-951). Tivozanib exhibits picomolar inhibitory activity against all three VEGF receptors, a multi-day T1/2 in humans, and demonstrates robust clinical activity demonstrated in renal cell carcinoma, the signal tumor type for VEGF pathway inhibition. Consistent with the variation in angiogenic phenotypes, variation in response to tivozanib was observed: a subset of these tumors exhibited exquisite sensitivity to tivozanib, whereas other tumors were significantly less sensitive. These results are in line with the clinical benefit of Sorafenib on patients with hepatocellular carcinoma. These data, taken together, strongly suggest that anti-angiogenesis therapy can be a potential treatment option for a subset of HCC patients. Since our HCC models captured the response of human HCCs, they provide a valuable tool for identification of biomarkers for patient selection. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A12.

Tumor Suppressor CLCA1 Inhibits Angiogenesis Via TGFB1/SMAD/VEGF Cascade and Sensitizes Hepatocellular Carcinoma Cells to Sorafenib.

CLIC1 Drives Angiogenesis in Hepatocellular Carcinoma by Modulating VEGFA

The LINC00152/miR-205-5p/CXCL11 Axis in Hepatocellular Carcinoma Cancer-Associated Fibroblasts Affects Cancer Cell Phenotypes and Tumor Growth.

Inhibition of the Wnt/β-catenin Signaling Pathway Improves the Anti-Tumor Effects of Sorafenib Against Hepatocellular Carcinoma.

Targeting KCTD1 As a Potential Novel Therapy Ameliorates Hepatocellular Carcinoma Progression Via the HIF-1α/VEGF Pathway

Bclaf1 promotes angiogenesis by regulating HIF-1α transcription in hepatocellular carcinoma

ANGPTL1 Interacts with Integrin Α1β1 to Suppress HCC Angiogenesis and Metastasis by Inhibiting JAK2/STAT3 Signaling.

The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma

Cancer‐Associated Fibroblast‐Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression

B‐cell Lymphoma‐2‐associated Transcription Factor 1 is Overexpressed and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma

1052 MicroRNA-218 Inhibits Cell Cycle Progression and Promotes Apoptosis in Colon Cancer Cells by Downregulating Oncogene BMI1

Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma.

CCL5/CCR5/CYP1A1 pathway prompts liver cancer cells to survive in the combination of targeted and immunological therapies

Sorafenib Enriches Epithelial Cell Adhesion Molecule–positive Tumor Initiating Cells and Exacerbates a Subtype of Hepatocellular Carcinoma Through TSC2‐AKT Cascade

HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma

Claudin-1 Silencing Increases Sensitivity of Liver Cancer HepG2 Cells to 5-Fluorouracil by Inhibiting Autophagy

NT157 Inhibits Hepatocellular Carcinoma Growth and Sensitizes Cells to Sorafenib

TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma

Transmembrane protein 147, as a potential Sorafenib target, could expedite cell cycle process and confer adverse prognosis in hepatocellular carcinoma

Abstract A12: Variation in Response to Triple VEGFR Inhibitor Tivozanib in Mouse Models of Hepatocellular Carcinoma

Analysis Of Signal Pathway Activation In Hepatocellular Carcinoma: Association With Clinical Outcomes To Sorafenib In Chinese Patients